BenevolentAI Investor Presentation Deck
BEN-8744 results and progress to date
2020
Target
validation
2019
Novel, potent advanced lead molecule developed within 2 years
TARGET IDENTIFICATION
Novel target for UC
Discovered using Benevolent
TargetID tools
PDE10 has zero linkage to UC in all
available biomedical literature
Experimentally validated in ex-vivo
UC colon samples from patients
refractory to SoC treatment
2021
CHEMISTRY
Candidate
nomination
Rapid and efficient lead
optimisation
Molecular Design tools enabled
rapid and efficient lead optimisation
Candidate nominated in Sep '21
Novel, potent, selective, peripherally
restricted PDE10. Inhibitor, with low
dose prediction
Only 2 years from programme
initiation
2022
Preclinical
2023
Phase I clinical study
CLINICAL DEVELOPMENT
Developing responder and
progression endotypes
We will develop responder and
progression endotypes, adding
molecular descriptors
These will inform our trial designs,
patient selection and target
identification in UC
Augmenting a further loop of
iteration on an enriched graph
Benevolent 15View entire presentation